MedCity News December 4, 2024
Eli Lilly obesity drug Zepbound led to 47% greater relative weight loss compared to Wegovy in a head-to-head clinical trial. The results could help Lilly differentiate its product from Novo Nordisk’s in the increasingly competitive market of obesity medications.
The battle for market share between the two leaders in the booming obesity drug sector has a new data point decidedly in favor of Eli Lilly. The Lilly drug Zepbound has topped Novo Nordisk’s Wegovy in a head-to-head clinical trial.
According to the preliminary Phase 3b results, treatment with Zepbound led to 47% greater relative weight loss compared to Wegovy, Lilly announced Wednesday. The pharmaceutical giant said more details will be published and presented at a medical meeting next year. But...
Today's Sponsors
Today's Sponsor